OncoMatch/Clinical Trials/NCT06731413
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Is NCT06731413 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Reduced Dose of Chemotherapy and Immunotherapy for non-small cell lung cancer.
Treatment: Reduced Dose of Chemotherapy and Immunotherapy — Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patients who receive reduced dose chemotherapy in combination with immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Biomarker criteria
Required: PD-L1 (CD274) tumor proportion score (TPS) of less than 50% (<50%)
PD-L1 tumor proportion score (TPS) of less than 50%
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1,000/μL; Platelets ≥ 75,000/μL; Hemoglobin (Hgb) ≥ 8.0 g/dL (transfusion permitted)
Kidney function
Creatinine clearance of <30 mL/min [excluded]
Liver function
Total bilirubin ≤ 2 x institutional upper limit of normal (ULN); AST/ALT ≤ 5.0 × institutional ULN
ANC ≥ 1,000/μL; Platelets ≥ 75,000/μL; Hemoglobin (Hgb) ≥ 8.0 g/dL (transfusion permitted); Total bilirubin ≤ 2 x institutional upper limit of normal (ULN); AST/ALT ≤ 5.0 × institutional ULN; Creatinine clearance of <30 mL/min [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify